Good MorningEquity markets gained over 1.0% on Friday to close at a new 1-year high. The move was inspired by softer-than-expected PCE price data that suggests the FOMC is near the end of its tightening cycle. The caution for investors is that inflation remains hot at 4.1% core, and the oil price is rising again. Oil prices underpin inflation; with WTI set to move to a multi-month high, inflation will accelerate again.
This week will be another trying 1 for investors. A host of earnings reports is due out this week on top of the monthly labor data. The NFP report is expected to show another solid increase in job creation and rising wages. The risk is two-fold; a hot figure will play into the idea that the FOMC is not through raising interest rates, while a cool 1 may foreshadow the recession that has loomed for the last year. Featured: I interviewed 600 crypto millionaires – here's what's coming (Ad) 
|
Markets | |
If you've looked at stock charts, you've likely heard of or seen moving averages. Dynamic curvy lines that continuously rise and fall represent them on the charts.
You can glean much information from using moving averages. Moving averages are some of the most commonly used chart indicators.... Read the Full Story |
|
From Our PartnersAs you may have seen over the last few weeks, I've been giving out special daily setups on my favorite ticker.
We’ve been taking these setups @ 10AM and so far, we've posted 28 different payouts …
Each of which were delivered at exactly 4PM as the market closed.
You see, these setups require zero oversight and have shown the power to deliver in the most chaotic market conditions.
And after a few weeks of fine-tuning … I knew it was time to let you in on The 4 PM Payout Plan.
That's why Jack Carter and I pulled back the curtain to reveal how we've been able to nail in a 96% win rate in the same window the market lost 11 trillion dollars in value. | | We also revealed how you can find and execute these setups on your own without any help at all. |
|
Markets | | Shares of Exxon Mobil (NYSE: XOM) fell by as much as 1.8% during the early hours of Friday's trading session; the decline is happening on a day when the broader markets (namely the S&P 500) are up by a third of a percent. The initial reaction can be attributed to markets digesting the latest fig... Read the Full Story |
|
Stocks | |
In today's ever-evolving investment landscape, technology has emerged as a clear standout, surpassing the broader market with its remarkable performance year-to-date. YTD, popular technology ETF Invesco QQQ (NASDAQ: QQQ) is up 44%, while the SPDR S&P 500 ETF (NYSE: SPY) is ... Read the Full Story |
|
|
Markets | |
Having led much of the equity rally this year, shares of tech titan Apple Inc (NASDAQ: AAPL) have taken a hiatus in recent weeks. They managed to tag a fresh all-time high on July 19, but as they head into the final trading day of July on Monday, they're less than $1 higher than where th... Read the Full Story |
|
Stocks | | Wall Street's rally got back on track Friday following more encouraging profit reports and the latest signal that inflation is loosening its chokehold on the economy.The S&P 500 rose 1% to its highest close in more than 15 months. The Dow Jones Industrial Average climbed 176 points, or 0.5% afte... Read the Full Story |
|
From Our PartnersWith the next presidential cycle heating up and Trump leading the charge, major market shifts are already taking shape.
For investors who position early, the opportunities could be significant.
That’s why we’ve just released a brand-new report:
📈 “5 Best Stocks to Buy Under Trump’s Presidency.” | | Get the full report here—and stay ahead of the curve. |
|
Markets | |
Shares of trucking and logistics giant Saia Inc. (NASDAQ: SAIA) are rising by as much as 3% during Friday's trading session, closing the week with sizeable bullish momentum in the company. The reaction comes as the firm releases its second quarter 2023 earnings results, which flashed som... Read the Full Story |
|
Markets | | The German economy is still failing to grow, figures showed Friday, as the country that should be the industrial powerhouse for all of Europe struggles with high energy prices, rising borrowing costs and a lagging rebound from key trading partner China. Economic output in Germany stagnated in the Ap... Read the Full Story |
|
Markets | | Europe's banking sector could withstand a severe economic downturn without depleting their financial buffers against losses, the European Central Bank said Friday.A survey of 98 large and medium-sized banks done by the ECB's supervisory arm in conjunction with the European Banking Authority showed t... Read the Full Story |
|
Markets | | Southwest Airlines said second-quarter earnings dropped 10% to $683 million as labor costs soared, offsetting record revenue at the start of the peak summer travel season.The airline also warned Thursday that a key revenue ratio will drop and non-fuel costs will rise in the third quarter.The shares ... Read the Full Story |
|
Markets | | Dozens of people protested in front of the Central Bank of Iraq in Baghdad and bank owners called for official action to stem a sharp increase in the dollar exchange rate Wednesday, after the United States blacklisted 14 Iraqi banks.Over the past two days, the market rate of the dollar jumped from 1... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. | View Today's Stock Pick |
|